Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind dose-response study of radium-223 for painful bone metastases in hormone-refractory prostate cancer
2004-000299-15Phase 2Completed
- Sponsor
- Algeta ASA
- Start
- Jul 2004
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of radium-223 dichloride in prostate cancer (PCa) (3 arms), sponsored by Algeta ASA. Primary endpoints: Pain response classification, Bone pain assessment and 2 more. Started Jul 2004; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-000299-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000299-15.